LENZ Therapeutics (LENZ) versus The Competition Head to Head Comparison

LENZ Therapeutics (NASDAQ:LENZ) is one of 289 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare LENZ Therapeutics to related businesses based on the strength of its dividends, earnings, risk, institutional ownership, profitability, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for LENZ Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	0	0	5	0	3.00
LENZ Therapeutics Competitors	1435	4548	11893	208	2.60

LENZ Therapeutics currently has a consensus target price of $31.33, suggesting a potential upside of 90.36%. As a group, “Biological products, except diagnostic” companies have a potential upside of 66.61%. Given LENZ Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than its competitors.

Insider and Institutional Ownership

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 38.4% of LENZ Therapeutics shares are owned by insiders. Comparatively, 16.3% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares LENZ Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	-33.12%	-27.96%
LENZ Therapeutics Competitors	-4,533.48%	-225.14%	-44.84%

Valuation & Earnings

This table compares LENZ Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
LENZ Therapeutics	N/A	-$124.65 million	-1.05
LENZ Therapeutics Competitors	$545.62 million	-$37.02 million	8.91

LENZ Therapeutics’ competitors have higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

LENZ Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, LENZ Therapeutics’ competitors have a beta of 1.10, meaning that their average share price is 10% more volatile than the S&P 500.

Summary

LENZ Therapeutics beats its competitors on 8 of the 13 factors compared.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.